As low- and middle- income countries (LMICs) continue to face health challenges from infectious disease, they are concurrently challenged by the rising burden of non-communicable diseases including cancer. The International Agency for Research on Cancer (IARC) estimates that by 2030, the annual number of new cancer cases worldwide will exceed 21 million and the number of cancer deaths will reach 13 million. The World Health Organization (WHO) estimates that 70% of all cancer deaths occur in LMICs. Changing economics in many countries around the world have meant changes in dietary and behavioral factors, several of which are linked to increased risk for cancers.
According to WHO, as many as 30% of all cancer deaths are attributable to dietary factors, …
June is Cancer Immunotherapy Awareness Month, an initiative to increase the public’s awareness of the revolutionary new treatment approach. Cancer immunotherapy utilises the immune system to fight the disease and represents the most immediate hope for curing patients with any type of cancer. BioMed Central and the Society for Immunotherapy of Cancer (SITC) are therefore pleased to announce the timely launch of the Journal for ImmunoTherapy of Cancer (JITC), an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
As the official journal of SITC, JITC will be the cancer immunotherapy community’s prime forum to discuss the critical issues in tumor immunology and cancer …
Clinical oncology in Western countries is currently characterized by preventative programs (which include early diagnosis), combined treatments (radio-chemo-surgery), reconstructive surgery, and, more recently, by tailored treatment with monoclonal antibodies or specific inhibitors based on newly identified cancer biomarkers. Clinical oncology in the rest of the world, which represents 85.3% of the Earth’s population, has different priorities, strategies and aims, which are often difficult to compare. Major differences are not only due to the different socio-economical conditions and the national health programs, but also to disparities in cancer burden and their etiopathogenesis, as well the population-based genetic susceptibility. A further major difference is the age-distribution of the population. In the Western world, the population is very much aged, with people aged …
Franco M Buonaguro and Sam M Mbulaiteye, Editors-in-Chief of Infectious Agents & Cancer, would like to invite you to submit your manuscript to a new thematic series, entitled “Burkitt Lymphoma, Beyond Discoveries” which will be published in the journal.
Burkitt Lymphoma (BL) is an aggressive non-Hodgkin lymphoma (NHL) that was first described by Dennis Burkitt in 1958 in Ugandan children. Since then, numerous breakthroughs, including the discovery of the Epstein-Barr virus (EBV), and its links to the disease, have been made. The most important of these discoveries has been the demonstration of curability of lymphoma which has re-invigorated efforts to use chemotherapy to treat cancer and helped establish some of the key principles of chemotherapy for …
The deadline to recommend an article for the BioMed Central Research Awards is fast approaching, with nominations closing on the 31st January.
Now in its 7th year, the awards will celebrate the best research published across BioMed Central’s portfolio of more than 240 open access journals in 2012. There are 10 refined categories covering all areas of Biology, Medicine and Health services research, as well as dedicated prizes for case reports, open data and advocacy, The awards this year will allow us to distinguish the articles that deserve recognition across several disciplines.
Each category will be overseen by a dedicated judging panel of internationally recognised leaders in …
In September 2009, Journal of Translational Medicine (JTM) and the then International Society for the Biological Therapy of Cancer (iSBTc) launched the Tumor Immunology and Biological Cancer Therapy section in the journal and with it JTM became a venue for the discussion of hot issues in tumor immunology which were highly relevant to translating novel immune interventions. Launched at a turning point in cancer immunotherapy, when considerable advances in understanding the relationship between the immune system and cancer started to translate to pioneering active immunotherapies, the section and journal quickly grew under the guidance of Section Editor Pedro Romero, and the renamed Society for ImmunoTherapy of Cancer (SITC), to become a …
Predictive, preventive and personalized medicine (PPPM) is positioned as one of the key components to the future of patient care. As outlined in an editorial The EPMA Journal, which recently moved from Springer to BioMed Central, aims to promote this paradigm change “from delayed interventional ‘disease care’ to PPPM as the medicine of the future” by disseminating reviews that cover at least two of the three aspects of PPPM.
One such recently published review article discusses the commonly-held belief that the nutritional supplement chromium picolinate (CrPic) is of benefit in the treatment of type 2 diabetic, obese and diabetes predisposed individuals. But as one of the authors and Editor-in-Chief, Olga Golubnitschaja, explains: …
New research published in the Journal of Translational Medicine’s Personalized medicine section outlines the discovery that germ line BAP1 defects are responsible for a novel cancer syndrome characterised by malignant mesothelioma, uveal melanoma, cutaneous melanoma and atypical melanocytic tumors, known as “melanocytic BAP1-mutated atypical intradermal tumors” (MBAITs).
Researchers from the University of Hawai‘i Cancer Center investigated two families with BAP1 defects and found an increase in the occurrence of mole-like melanocytic lesions and were able to determine that these benign tumors carried BAP1 mutations. The article concludes that the presence of melanocytic tumors can be used as a visual marker for identifying individuals with germ line BAP1 mutations and, as a result, are at higher risk of …
the launch of DARU Journal of
Pharmaceutical Sciences last month, BioMed Central is pleased to add two
more journals from the Tehran University of Medical Sciences (TUMS) to its
portfolio. Journal of Diabetes & Metabolic Disorders and Iranian Journal of Environmental Health Science & Engineering have now published their first articles with us.
of Diabetes & Metabolic Disorders provides a forum for scientific
inquiry of the highest standard in the fields of diabetes and metabolic
disorders. As well as an editorial by
Editor-in-Chief Bagher Larijani, the inaugural articles include original research on the Anti-inflammatory effect of insulin in
rabbits with hypercholesterolemia as well as an …
DARU Journal of Pharmaceutical Sciences has published its
inaugural articles with BioMed Central. Amongst these are an editorial by Editor-in-Chief Mohammad Abdollahi
which highlights the need for a quality, open-access journal in the field of
pharmaceutical sciences. The launch
articles also include original research on enhancing indomethacin release in vitro, and propylene glycol tolerance
in neonates, as well as a review article on the status of lead pollution and
toxicity in Iran.
The word ‘DARU’ is derived from
the Persian name for drug and the journal aims to act as a platform for all
areas of drug conception, design, manufacture, classification and
assessment. The journal is …